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Each passing year, statisticians, toxicologists and related scientists exert increasing pressure on the pathologist to carry out necropsy procedures and histopathologic examination of tissues "blindly". The intensity of the feeling behind these requests can be gauged from an event that occurred in May of 1973 at a meeting of the National Academy of Sciences entitled "Conference on Carcinogenesis Testing in the Development of New Drugs". In response to a question, a statistician on one of the panels recommended that all specimens intended for pathologic examination be sent to the pathologist without identification in order to remove bias. To my surprise, the large audience erupted with spontaneous applause following his statement. No similar response greeted the response of the senior pathologist on the panel when he strongly disagreed with the statistician and endeavored to present his reasoning.
Since we cannot wish the problem of blind evaluation out of existence and an unreasoning negative response would make the pathologist appear to be an uncooperative or obstructionist member of the team, I believe that the best approach to the problem is to examine its components in an objective, rational manner. That is what I propose to do in this paper.
The first question to be asked is, "what are the advantages of using blind evaluation methods in the histopatholo~y examination"? The second question is, "what are the disadvantages"? The third question is "after weighing the advantages and disadvantages, is there sufficient jus~ification for routine usage of blind evaluation techniques in the histopathology portion of toxicity studies"? The fourth question is, "do blind evaluation tech-' niques have merit when applied judiciously to selective problems"? The fifth question is, "are there viable alternatives to blind evaluation techniques that can be used in their place to serve as a quality control safeguard against bias that has been introduced into histopathologic evaluations"? In the following paragraphs, I shall present some of my thoughts on these important questions, thoughts that are not comprehensive but that hopefully will serve as a catalyst to the reader.
THE ADVANTAGES OF BLIND EVALUATION
When one queries statisticians and toxicologists about the advantages of blind evaluation, the responses are invariably vague or illdefined and can be summed up by an expression of belief on the part of these scientists that the use of the method will serve to eliminate bias. The claim by statisticians and toxicologists that blind evaluation techniques eliminate or reduce bias in histopathologic studies represents a superficial analysis of the problem. The pathologist needs to know much more about the nature of the bias qualitatively and quantitatively. Will pathologic observations and diagnoses made in the course of an "open" study by one pathologist differ significantly from the observations and diagnoses made by the same pathologist on the same study using blind evaluation techniques? What will be the magnitude of the differences? 10-20%? 80-90? Will the pathologic diagnoses be essentially the same in the "open" and "blind" studies but will the severity (grading) of the lesions be more severe in the treated animals? Qualitative and quantitative scientific data with regard to the bias that may insidiously creep into histopatho-logic evaluations are unfortunately lacking at this time.
The development and widespread application of blind evaluation techniques occurred with controlled clinical trials on new and untested new drugs for the treatment of human disease. The term "double blind" was coined by Dr. Harry Gold and his associates who explained the purpose of double blind techniques as follows: "The purpose of the double blind technique is to eliminate bias resulting from any preference, conscious or unconscious that the doctor or patient may have for a particular remedy". If we substitute ~~j R d e v a~u a~~o n technique for d o u~~e ~~~~d technique; pathologist for doctor; eliminate the word patient and substitute pathologic diagnosis for remedy, the definition would be appropriate for histopathologic examinations. Although most clinical investigators accept the hypothesis that double blind clinical trials reduce or eliminate bias, the scientific basis for its claims has been questioned (1).
It may be worthwhile to compare the application of blind evaluation techniques to clinical trials on the one hand and the histopathologic evaluation of tissues on the other. Is the widespread ap~licatjon and acceptance in the former case ips0 facto justification for its application in the latter case? I think not because there are very major differences between these applications. In the clinical trial, very large biasing factors may pervade the interpretation of the results of drug therapy because the interpretation of the efficacy of treatment is determined (a) by the patient whose mind may be influenced by numerous factors including the doctor-patient relationship, the expectations of the patient regarding the outcome, conscious or unconscious communication occurring between patient and doctor, nurse or other clinic personnel, spontaneous variations in the disease process, lack of adequate concurrent controls and imprecise measurements used to evaluate the results of therapy and (b) by the doctor who may have strong preconceived feelings or wishes with regard to the outcome of the results of therapy. By comparison, in a toxicity study where the question of the efficacy of the test compound is irrelevant, it is less likely that the pathologist would have preconceived ideas (bias) regarding the presence or absence of a significant histopathologic effect. In most instances he would be a neutral observer. Furthermore, the histopathologic examination of tissues in a toxicity study is a less complex process than that involved in evaluating the efficacy of a new drug in human test subjects. One observes a wide variety of tissue or cellular patterns in either normal (healthy) or diseased states. In differentiating the normal from the pathologic state, the pathologist draws upon visual memory and basic prinkiples that he has learned in general and special pathology and has reinforced by years of practise. Thus, the pathologist must carefully observe any changes in tissues or cells that deviate from "normal", must characterize the nature of the changes, must interpret the pathologic changes in terms of prior knowledge and experience and finally must assign an appropriate diagnostic term that attempts to characterize or identify the disease process. Given these conditions, it is highly improbable that a pathologist in the evaluation of treated tissues in an "open" study will perceive pathologic changes where none exist; nor is it very likely in examining the tissues of control animals that the pathologist will entirely miss a lesion because he.is aware of the treatment accorded the animal. Biasing factors if they occur would most likely be expressed in the severity of the grading of observed lesions. K n o~~l e d g e of which animals were controls, which received treatments and which received the highest dose of the test compound could conceivably weight the evaluation of the severity of the observed lesions toward the treatment groups.
It is generally assumed by statisticians who often are not trained in the biological sciences that bias is an undesirable component and should be excluded from toxicity studies. However, there are circumstances where bias may be a positive rather than a negative factor. For example, in the histopathologic examination of thousands of tissues in the course of a toxicity study, the pathologist must complete his review expeditiousIy if the objectives are to be accomplished. With this type of review, it is possible to miss subtle lesions. If clinical function tests of liver, kidney and thyroid are run and abnormalities of the thyroid gland are reported, for example, the pathologist's review of the thyroid gland will of necessity be more thorough than the routine examination and if a subtle lesion exists that could account for the observed abnormal thyroid function test, prospects for detecting the lesion will be enhanced. In this instance, the bias created by knowledge of an abnormal thyroid function test has functioned as a positive rather than as a negative factor in detecting the correct diagnosis.
Of the many factors that impinge upon the process of histopathologic examination of tissues, there are a number that we should mention that operate independently of the blind evaluation technique and will neither be altered nor eliminated by it. Among these factors are: (1) the inherent perceptiveness and skill of the observer, (2) the qualitative level of education, training and experience of the pathologist, (3) the level of "background noise" that the observer carries with him to the microscopic examination (an analogy to this would be the electronic noise generated by a high-fidelity system independently of the audio signal but capable of modifying or distorting its perception), and (4) diurnal fluctuations in mood, feelings, nutritional state etc.
THE DISADVANTAGES OF BLIND EVALUATION
Although statisticians and toxicologists blithely recommend the use of blind evaluation techniques, I doubt that many are aware of the formidable array of disadvantages (scientific as well as economic) that accompany the use of the technique. Let us consider some of them.
(1) Loss of identification of the concurrent control animal tissues which normally serve as a baseline guide to differentiate normal from pathologic tissues in a n "open" study. A pathologist without the control group as a reference point can identify with the pathologist who was described as having his feet firmly planted in mid-air. The time required to evaluate tissues in the absence of a control group is inordinately prolonged. Loss of the identity of the concurrent control group is perhaps the most important disadvantage of using blind evaluation techniques in histopathologic evaluations.
Optimal results in an "open" histopathology study are obtained when a careful detailed examination is made of control tissues prior to examination of treated tissues in order to. establish a baseline point of reference. This approach would also tend to neutralize the potential bias of overevaluating the treated tissues vis-a-vis the control tissues.
(2) The blind evaluation technique imposes a rigid system upon the pathologist, a sort of intellectual straitjacket. The research-minded pathologist hunts for serendipitous scientific clues early in the review process. If the search is successful, it can lead to the discovery of important original observations. Also, serious errors due to the introduction of extraneous chemicals into the experiment can be detected quickly and months of delay can be averted. The blind evaluation method discourages the pathologist from pursuing interesting leaps because all correlations between the test co'mpound and any pathologic effects must await the reading of all the tissues and the breaking of the code. By that time (which may be after reading thousands of tissues) the study is too far advanced to investigate new directions and thus scientific research and creativity are inhibited.
(3) Routine use of the blind evaluation method in histopathology studies poses a threat to the hard-earned role of the pathologist as a full professional member of the toxicology team. If the responsibility for breaking the code for pathologic diagnoses upon completion of the histopathology review is assigned to either the statistician or the toxicologist, the role of the pathologist in the toxicity study is diminished to that of providing technical assistance. Since the origin of the specialty of pathology, it has been difficult for pathologists to obtain information that is essential in order to practise the specialty in a professional manner. Routine employment of the blind evaluation method will tend to compound this problem, to reduce professionalism and ultimately may discourage creative young scientists from pursuing a career in pathology.
(4) The staff required to carry out a blind evaluation is larger than one required for an "open" study. There is duplication in record keeping. Records are incomplete until the completion of the blind histopathology evaluation at which time they must be completed. Chances for mix-ups in animal tissues are increased since the identity of the treatment group is an important marker for checking or double-checking records and identifying errors.
(5) To truly carry out a blind study, great care must be taken to conceal the identity of each animal or tissue with respect to treatment at numerous points inthe process.
Otherwise, it would not be very difficult for an astute observer to break the code. It would be of interest to know how many of the studies that are designated "blind studies" truly represent blind evaluation and how many merely pay lip service to the concept.
(6) Finally, we d o not know with any degree of precision for a given experiment what will be gained as a result of assuming the many burdens imposed by the routine use of blind evaluation techniques.
Following the above review of the relative advantages and disadvantages of the blind evaluation method, I have reached the conclusion that the advantages are insufficently well-known or defined to offset the formidable array of disadvantages and therefore the method should not be routinely employed in histopathology examinations that are part of toxicity studies.
As a practising pathologist, I have found blind evaluation to be valuable in two different situations: (1) in the initial study of unknown problem slides in diagnostic pathology where one's powers of observation can be considerably sharpened, and (2) in the reevaluation of suspect, low-grade lesions in toxicity studies that fall in the "grey zone" between normal and pathologic where blind identification of the lesion in treated animals close to 100% of the time provides objective confirmation that the lesion exists as a distinct entity and is related to treatment.
Even if we were able to persuade our colleagues in statistics and toxicology through a concerted educational effort that routine use of blind evalatuion methods in histopathology examinations is unjustified, it is unlikely that the problem will disappear. What our col-leagues seek is some sort of quality control procedure that will serve to detect the occurrence of any undesirable bias in the experiment at hand. This is a legitimate concern and deserves our serious attention. I know of no simple solution to this problem. What is needed is a quality control procedure that is both sensitive and practicable.
.J One proposal that has been put forth by an eminent pathologist is that a certain percentage (perhaps 10%) of all slides comprising a study be read blindly independently of the "open" review. Then a comparison of the "blind" and "open" diagnoses would hopefully help to detect biasing factors. However, discussion of the pitfalls in this proposal as in other proposals that have been made are beyond the scope of this report.
The design of a n adequate quality control procedure will be greatly aided by the generation of scientific data on the nature of biasing factors that may affect histopathology evaluations made in conjunction with toxicity studies.
